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Inactivation of Germline Mutant APC Alleles by Attenuated Somatic
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Adenomatous Polyposis
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Germline mutations of the adenomatous polyposis coli (APC) tumor-suppressor gene result in familial adenomatous
polyposis (FAP). Patients with FAP typically develop hundreds to thousands of benign colorectal tumors and early-
onset colorectal cancer. A subset of germline APC mutations results in an attenuated FAP (AFAP) phenotype, in
which patients develop fewer tumors and develop them at an older age. Although a genotype-phenotype correlation
between the locations of APC germline mutations and the development of AFAP has been well documented, the
mechanism for AFAP has not been well defined. We investigated the mechanism for AFAP in patients carrying a
mutant APC allele (APCAS9) that has a mutation in the alternatively spliced region of exon 9. APCAS9 was found
to down-regulate b-catenin–regulated transcription, the major tumor-suppressor function of APC, as did the wild-
type APC. Mutation analysis showed that both APCAS9 and the wild-type APC alleles were somatically mutated in
most colorectal tumors from these patients. Functional analysis showed that 4666insA, a common somatic mutation
in APCAS9 in these tumors, did not inactivate the wild-type APC.Our results indicate that carriers of APCAS9 develop
fewer colorectal tumors than do typical patients with FAP because somatic inactivation of both APC alleles is
necessary for colorectal tumorigenesis. However, these patients develop colorectal tumors more frequently than
does the general population because APCAS9 is inactivated by mutations that do not inactivate the wild-type APC.
Introduction
Familial adenomatous polyposis (FAP [MIM 175100])
is an autosomal dominant inherited disease that predis-
poses patients to colorectal cancer. Patients with FAP
typically develop hundreds to thousands of colorectal
adenomas in their 2d or 3d decades of life. If not sur-
gically removed, some of these benign adenomas will
progress to malignant carcinoma. FAP is caused by
germline mutation of the adenomatous polyposis coli
(APC) tumor-suppressor gene (Groden et al. 1991; Jos-
lyn et al. 1991; Kinzler et al. 1991; Nishisho et al. 1991).
Somatic mutations in APC also occur in most sporadic
colorectal tumors (Miyoshi et al. 1992; Powell et al.
1992; Miyaki et al. 1994). Consistent with Knudson’s
two-hit hypothesis that both alleles of a tumor-suppres-
sor gene are mutated in a tumor (Knudson 1985), mu-
tation of both APC alleles has been demonstrated in
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FAP-related and sporadic colorectal tumors (Miyoshi et
al. 1992; Powell et al. 1992; Miyaki et al. 1994). The
formation of most colorectal tumors is believed to be
initiated by the mutation of both APC alleles (Kinzler
and Vogelstein 1996).
APC expresses a major mRNA of ∼10.5 kb that en-
codes a protein of 2,843 amino acids (Groden et al.
1991; Joslyn et al. 1991; Kinzler et al. 1991). APC exon
15 contains 6.5 kb of the 3′ coding region and includes
a mutation-cluster region in which most somatic mu-
tations occur (Groden et al. 1991; Joslyn et al. 1991;
Miyoshi et al. 1992; Miyaki et al. 1994). The tumor-
suppressor function of APC is believed to involve the
regulation of b-catenin–regulated transcription (CRT
[Korinek et al. 1997; Morin et al. 1997; Polakis 1999;
Peifer and Polakis 2000]). b-Catenin can associate with
the Tcf/Lef family of DNA-binding proteins and can
form DNA sequence–specific transcription complexes
(Behrens et al. 1996; Molenaar et al. 1996; Korinek et
al. 1997). APC regulates CRT by associating with b-
catenin, together with glycogen synthase kinase-3b
(GSK3b) and axin or conductin, and promoting its deg-
radation (Munemitsu et al. 1995; Rubinfeld et al. 1996;
Behrens et al. 1998; Hart et al. 1998; Polakis 1999;
Peifer and Polakis 2000). The identification of human
and rat colorectal tumors that do not have inactivating
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mutations in APC but instead express b-catenin mutants
resistant to APC-mediated regulation strongly supports
the hypothesis that APC exerts its tumor-suppressor
function by regulation of CRT (Morin et al. 1997; Dash-
wood et al. 1998; Sparks et al. 1998; Takahashi et al.
1998).
In addition to the major mRNA, APC also expresses
several minor alternatively spliced mRNA (Groden et
al. 1991; Samowitz et al. 1995). One alternatively
spliced APC mRNA, APCdA9, lacks 303 nucleotides of
the alternatively spliced region of exon 9 (Groden et al.
1991). The APCdA9 protein encoded by APCdA9 con-
tains all domains known to be necessary for regulation
of CRT (Groden et al. 1991; Munemitsu et al. 1995),
although this function could be impaired by altered
three-dimensional structure.
Patients with a form of FAP called “attenuated FAP”
(AFAP) develop fewer colorectal tumors, and at older
ages, than do patients with typical FAP (Lynch et al.
1992, 1995). Mounting evidence indicates that individ-
uals carrying an APCAFAP allele usually develop AFAP
(Spirio et al. 1993; van der Luijt et al. 1995, 1996; Friedl
et al. 1996; Soravia et al. 1998), although there could
be significant variation in the phenotype of individuals
carrying the same germline mutation (Brensinger et al.
1998; Soravia et al. 1998). APCAFAP includesAPC alleles
with a germline mutation in the first four coding exons
(APC1–4), in the alternatively spliced region of exon 9
(APCAS9), or in the 3
′ half of the coding region (APC3H;
for descriptions of alleles, see the Appendix).
There are two alternative genetic explanations for
how patients carrying APCAFAP develop AFAP, according
to Knudson’s two-hit model. One is that APCAFAP does
not have tumor-suppressor activity and that a single
somatic mutation inactivating the wild-type APC allele
will lead to colorectal tumorigenesis. This is similar to
what happens in patients with FAP and could explain
why patients with AFAP are susceptible to development
of colorectal tumors. However, for patients with AFAP
to have the attenuated phenotype, inactivation of the
wild-type APC allele must either occur less frequently
than in typical FAP or not be sufficient for tumorigen-
esis. Alternatively, the APCAFAP alleles still have tumor-
suppressor activity, and somatic inactivation of both
APC alleles is necessary for tumor formation. This re-
sembles the development of sporadic colorectal tumors
in people without a germline APC mutation and could
explain why patients with AFAP have the attenuated
phenotype. However, APC must be inactivated more
readily in patients with AFAP than in the general pop-
ulation, because patients with AFAP are still predis-
posed to colorectal tumorigenesis.
A study of colorectal tumors from patients carrying
APC1–4 demonstrated that some of these tumors had
two somatic mutations (Spirio et al. 1998). A specific
APC mutation, 4666insA, was found frequently in these
tumors and was found to occur at the APC1–4 allele. It
was proposed that, for tumors to form in these patients,
the wild-typeAPC allele must be somatically inactivated
first and that then the germline mutant allele must be
somatically inactivated by either small mutations or loss
of heterozygosity (LOH). However, it remained unclear
why these patients were predisposed to colorectal tu-
morigenesis. The present report describes our investi-
gation of the underlying mechanism of AFAP in patients
carrying APCAS9.
Patients, Material, and Methods
Patients and Tumor Samples
The two patients were from a family carrying a germ-
line nonsense mutation at APC codon 332 (CGArTGA;
data not shown). Patient 1 (a 47-year-old male) had 30
colorectal adenomas !2 mm and a history of 2 1-cm
adenomas that had been previously excised. Patient 2 (a
15-year-old male) had three colorectal adenomas !1
mm. Neither patient had a history of cancer or surgery.
Informed consent for collection of tumor samples was
obtained from patients, and the research was approved
by the M.D. Anderson Cancer Center’s institutional re-
view board.
The adenomas were separated from adjacent normal
tissues by microdissection of fresh biopsy samples. Single
crypts were isolated from fresh adenoma biopsies by a
modification of a method described elsewhere (Cheng et
al. 1984). In brief, fresh mucosal biopsy samples were
incubated at 37C for 10 min in Ca2- and Mg2-free
Hanks’ balanced salt solution containing 30 mM EDTA,
then were vibrated gently to separate the epithelium
from the stroma. The isolated crypts were then incubated
in a buffer containing CaCl2 and MgCl2, to restore nor-
mal chromatin structure and crypt architecture. Finally,
the crypts were fixed first in 10% buffered formalin for
2 h, then in 70% ethanol overnight. Confocal micros-
copy of propidium iodide–stained single crypts con-
firmed the complete isolation of the epithelial crypt cells
from the surrounding mucosa.
Mutation Detection
Genomic DNA was isolated from individual crypts by
proteinase K digestion, followed by phenol-chloroform
extraction and ethanol precipitation. Mutations of APC
were detected using the in vitro synthesized-proteinassay
(IVSP), followed by DNA sequencing, as described else-
where (Powell et al. 1993; Su et al. 2000). All tumors
were analyzed for codons 686–1686, and tumors with
only one somatic mutation in this region were then an-
alyzed for codons 1554–2843. Templates for IVSP were
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generated by nested PCR. Primers used for the first-step
PCR were 5′-CAAATCCTAAGAGAGAACAAC-3′ and
5′-GACGCAGATGCTTGCTGG-3′ for codons 686–
1686 and 5′-GATTTTCTTGTTCATCCAGCC-3′ and
5′-GAGTGGATCCCAAAATAAGACC-3′ for codons
1554–2843. PCR was performed using the Expand Long
Template PCR System (Boehringer-Mannheim). One
tenth of the genomic DNA obtained from a single crypt
was used in the first-step PCR. The reaction consisted
of 1 cycle of 2 min at 92C; 20 cycles each of 15 s at
92C, 1 min at 55C, and 2.5 min at 68C; and 1 cycle
of 5 min at 68C. One microliter of the first-step am-
plification product was used in the second-step PCR. The
PCR and the coupled in vitro transcription and trans-
lation reactions were performed as described elsewhere
(Su et al. 2000).
Plasmids
The reporter plasmids for assessment of CRT,
pTOPFLASH and pFOPFLASH were gifts from Dr. H.
Clevers (University Hospital, the Netherlands) and carry
the luciferase gene regulated by wild-type and mutant T
cell factor–binding motifs, respectively (Korinek et al.
1997). The control reporter pcDNA3Luc was generated
by insertiing the coding region of luciferase downstream
of the cytomegaloviral early promoter in the plasmid
pcDNA3 and was a gift from Drs. M.-C. Hung and D.-
H. Yan (M.D. Anderson Cancer Center). The plasmid
pBI-MCS-EGFP (Yu et al. 1999) and plasmids contain-
ing the wild-typeAPC andAPC1309 and were gifts from
Drs. K.W. Kinzler and B. Vogelstein (Johns Hopkins Uni-
versity). The plasmid pUHD15-1 (Gossen and Bujard
1992) was provided by Dr. H. Bujard (Universita¨t Hei-
delberg), and pRL-TK was purchased from Promega.
APCdA9 was generated by replacement of a fragment
of the full-length APC cDNA, containing the entire exon
9, by a corresponding fragment that did not have the
alternatively spliced region of exon 9 obtained by reverse
transcription–PCR. APC1556 was generated by replace-
ment of a fragment of wild-type APC containing codon
1556 by a corresponding PCR fragment containing an
A inserted at codon 1556. Fragments that replaced the
wild-type APC were completely sequenced, to ensure
that there were no unintended sequence alterations.
APCdA,1556 was generated by replacement of the 5′
2.2-kb BamHI-StuI fragment of APC1556 by the cor-
responding fragment from APCdA9.
Three different expression vectors, pCMV-NEO-BAM
(Baker et al. 1990), pCIN, and pTBI, were used to ex-
press APC. To generate pCIN, the SalI-BamHI fragment
containing rabbit b-globin intron 2 and part of its flank-
ing exons was isolated from pCMV-NEO-BAM, the SalI
site was filled in, and the fragment was inserted between
the BamHI and the filled-in HindIII site of pcDNA3
(Invitrogen). To generate pTBI, the HindIII-XhoI frag-
ment containing b-globin intron was isolated from
pCIN, the HindIII site was filled in, and the fragment
was inserted between the PvuII and XhoI sites of pBI-
MCS-EGFP. APC cDNAs were inserted at the BamHI
site of pCIN and pCMV-NEO-BAM and at the BglII site
of pTBI.
Cell Lines
All cell lines were obtained from American Type Cul-
ture Collection. MCF7 is a human breast cancer cell line.
SW480, DLD-1, and HCT116 are human colon cancer
cell lines. SW480 and DLD-1 express the wild-type b-
catenin that can be regulated by APC, whereas HCT116
expresses a mutant b-catenin that is resistant to APC
regulation (Morin et al. 1997).
Results
We first determined whether APCdA9 had tumor-sup-
pressor activity. The alternatively spliced APCdA9 tran-
script expressed from APCAS9 does not contain the germ-
line mutation and is expected to express the same
APCdA9 protein that is expressed from the wild-type
APC. Thus, APCAS9 would have tumor-suppressor ac-
tivity if APCdA9 has tumor-suppressor activity. We com-
pared the ability of APCdA9 to regulate CRT with that
of the wild-type APC and of the mutant APC1309, a
common APC mutant deficient in regulation of CRT
(Nagase and Nakamura 1993; Miyaki et al. 1994;
Morin et al. 1997). As it did in previous reports of the
wild-type APC (Korinek et al. 1997; Morin et al. 1997),
APCdA9 reduced the expression of a reporter controlled
by CRT (pTOPFLASH) but did not significantly affect
the expression of reporters that were not controlled by
CRT (pcDNA3Luc and pFOPFLASH; fig. 1). These re-
sults suggested that APCAS9 had tumor-suppressor activ-
ity. However, because of the normally low expression
level of APCdA9 (Groden et al. 1991), it was not clear
whether APCAS9 needed to be somatically mutated for
colorectal tumors to form in APCAS9 carriers.
We next examined whether APCAS9 was somatically
mutated in colorectal tumors from patients carrying
APCAS9. Nine early colorectal adenomas in two patients
from a family carrying APCAS9 were examined for so-
matic mutations in APC exon 15. Single crypts were
isolated from each tumor, and genomic DNA was pre-
pared from each crypt, for use in the analysis. All nine
tumors had somatic mutations, including one that had
LOH at the APC locus, and five of them had somatic
mutations in both APC alleles (fig. 2 and table 1). DNA
sequencing of APC exon 9 of the tumor having loss of
one APC allele showed that the allele lost was APCAS9
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Figure 1 Regulation of CRT by APCdA9. SW480 cells were
transfected with the combination of pCMVbgal, a reporter plasmid
(pTOPFLASH, pFOPFLASH, or pcDNA3Luc), and an APC expres-
sion vector, as indicated. Results of three separate experiments using
pCIN to express APC are shown. The activities of the wild-type APC
and APCdA9 in the regulation of CRT are compared with that of
APC1309. Similar results were obtained using pCMV-NEO-BAM to
express APC (data not shown).
Figure 2 Detection of somatic APC mutation. The result of
IVSP analysis of codons 686–1686 of a representative single crypt from
each tumor is shown. The use of single isolated crypts in this assay
allowed the easy detection of LOH in tumor 1-2. “F” indicates the
position of the full-length product presented in tumors 1-1, 1-3A, 1-
4, and 1-5. Dots indicate mutant products. The positions of the mo-
lecular-weight standards are shown on the left.
(data not shown). Four of these nine tumors had the
4666insA mutation (table 1). To determine which APC
allele had 4666insA, a DNA fragment containing this
mutation and two intragenic polymorphic nucleotides,
4479 and 5034 (Nagase et al. 1992; Powell et al. 1992),
was amplified by PCR, cloned, and sequenced. The al-
lelotype of the wild-typeAPC allele, with regard to these
two polymorphisms, was determined by sequencing of
a similar PCR product amplified using DNA from the
tumor that had lost the APCAS9 allele. The results
showed that 4666insA occurred in APCAS9 in all three
tumors from patient 1 (data not shown). The allele car-
rying this mutation in the tumor from patient 2 could
not be determined because he was homozygous for these
two polymorphic nucleotides. The allele carrying
4616delAG in a tumor from patient 1 also was found
to be APCAS9 (data not shown). Therefore, somatic mu-
tation of the APCAS9 allele could be demonstrated in
eight of the nine tumors examined, including three of
the four tumors that had only one somatic APC mu-
tation identified.
The high frequency of the 4666insA mutation in these
tumors—and, specifically, in the APCAS9 allele—sug-
gested that, although this mutation could inactivate
APCAS9, it might not significantly affect the function of
wild-type APC. To test this hypothesis, the 4666insA
mutation was introduced into APC and APCdA9, to
generate APC1556 and APCdA,1556, respectively. Im-
munoblot analysis confirmed that this mutation resulted
in the truncation of APC protein (fig. 3A). The ability
of these forms of APC to down-regulate CRT was then
examined. As expected, APC and APCdA9 effectively
regulate CRT in both SW480 and DLD-1 cells but not
in HCT116 cells (fig. 3B). The 4666insA mutation did
not appear to affect the activity of APC and APCdA9
in SW480 cells. This mutation reduced, but did not
abolish, their activity in DLD-1 cells. Consistent with
its ability to regulate CRT, APC1556 was able to reduce
the b-catenin–protein level in SW480 cells (fig. 3C).
These results showed that the 4666insA mutation did
not abolish the function of APC or APCdA9.
Discussion
We have provided evidence that APCAS9 has tumor-sup-
pressor activity (i.e., regulation of CRT) and that it is
somatically mutated in colorectal tumors in APCAS9 car-
riers. Somatic mutations at the APCAS9 allele were iden-
tified in eight of the nine tumors examined. This finding
supports the premise that all nine tumors had somatic
mutations in both APC alleles, with some of these mu-
tations probably in APC regions that we did not ex-
amine. The absence of the wild-type IVSP product in
those single crypts having two somatic mutations
strongly supports the possibility that both somatic mu-
tations occurred in the same cell (fig. 2). Because all
tumors examined were !2 mm in diameter, somatic in-
activation of both APC alleles was most likely to be
necessary prior to colorectal tumorigenesis in these pa-
tients. This would explain why patients carrying APCAS9
develop fewer tumors, and at older ages, than do patients
with typical FAP.
Somatic mutations of both the wild-type and the
germline mutant APC alleles was reported for some co-
lorectal tumors from patients with AFAP who carry
APC1–4 (Spirio et al. 1998). However, the rate of double
somatic mutations is significantly higher in tumors with
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Table 1
Somatic APC Mutations
PATIENT
TUMOR SOMATIC MUTATION(S) CODON(S) AFFECTED
NO. OF CRYPTS
Examined
With
Mutation
1-1 4666insAa 1556 5 5
1-2 3896del11, LOHb 1298–1301 11 11
1-3A 4666insAa 1556 12c 4
1-3B 3158delA, 4392delAG 1053, 1465–1466 12c 8
1-4 4616delAGa 1539–1540 5 3d
1-5 4216delAG 1406 5 5
1-6 2562delGA, 4666insAa 855, 1556 5 5
2-1 3925del5, R1450X 1309–1310, 1450 7 6e
2-2 R1114X, 4666insA 1114, 1556 7 6d
a In APCAS9 allele.
b Lost allele was the APCAS9 allele.
c Isolated from what appeared to be one adenoma. The different mutation patterns
suggest that either the adenoma was heterogeneous or two adjacent adenomas were
confluent.
d Remaining crypts did not have mutations.
e Remaining crypt had only 3925del5.
APCAS9, which we examined, than in those with APC1–4,
which have been reported elsewhere (5/9 vs. 7/35 [Spirio
et al. 1998]; , Fisher’s exact test). The proportionP ! .05
of tumors having LOH as one of the double somatic
mutations is significantly lower in tumors with APCAS9
than that reported in tumors with APC1–4 (1/5 vs. 6/7
[Spirio et al. 1998]; ), although the overall ratesP ! .05
of LOH in these two groups of tumors are comparable
(1/9 vs. 8/66 [Spirio et al. 1998]; ) and are similarPp .7
to that reported for FAP-associated adenomas (Miyaki
et al. 1994). These differences could reflect the biolog-
ical differences between these two mutant APC alleles.
The difference also may be partly due to the greater
sensitivity of our method, which analyzes single crypts,
for detection of mutations. A drawback of both studies
is that each examined tumors from patients in a single
family. Additional investigations of tumors from other
families should provide more-conclusive information.
Patients with AFAP who carry APCAS9 are predis-
posed to colorectal tumorigenesis despite their at-
tenuated phenotype. Therefore, the APC gene in these
patients must be somatically mutated more easily than
it is in the general population. One possibility is that
germline mutations increase the mutation rate of AP-
CAS9. Increased somatic mutation frequency has been
demonstrated in the APCI1307K allele, and this may
explain why APCI1307K carriers have an increased risk
of colon cancer (Laken et al. 1997; Gryfe et al. 1998,
1999). Although the possibility that APCAS9 alleles have
an increased mutation rate cannot be completely ruled
out, we do not have evidence for it. Instead, we propose
that APCAS9 alleles are inactivated more easily because
they can be inactivated by mutations that do not in-
activate wild-type APC. The 4666insA mutation is com-
mon in tumors from patients with AFAP who carry
either APCAS9 or APC1–4 (Spirio et al. 1998; present
study). In contrast, this mutation was rarely found in
sporadic colorectal tumors or tumors from patients with
typical FAP (Powell et al. 1992; Miyaki et al. 1994).
Although the 4666insA mutation occurs at a mono-
nucleotide repeat, it is not caused by increased micro-
satellite instability in tumors from patients with AFAP
(Spirio et al. 1998). We suggest that the 4666insA mu-
tation may occur frequently because it arises within a
stretch of six As and that it is rarely found in non–AFAP-
associated colorectal tumors because it only slightly im-
pairs the tumor-suppressor function of the wild-type
APC. However, this apparently weak mutation may be
able to inactivate the residual activity of APCAS9 because
of the normally low level of APCdA9 (fig. 4). Additional
studies of tumors from patients with AFAP who carry
different germline APC mutations will be needed to pro-
vide additional support for this hypothesis.
APC1556 was found to down-regulate CRT, although
it lacks any conductin-binding domains and therefore
is unlikely to interact with axin or conductin directly
(Behrens et al. 1998). However, APC1556 contains all
three 15-amino-acid– and three of seven 20-amino-
acid–repeat sequences that interact with b-catenin (Su
et al. 1993; Munemitsu et al. 1995). Because axin binds
b-catenin and GSK3b directly (Behrens et al. 1998; Hart
et al. 1998), APC1556 could associate with b-catenin/
axin/GSK3b complex and promote the degradation of
b-catenin, albeit less efficiently than do APC proteins
that can bind axin directly. This hypothesis is consistent
with results of a study comparing the CRT activity in
mouse embryonic stem cells expressing different Apc
mutants (Smits et al. 1999).
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Figure 3 Regulation of b-catenin by APC1556. A, Expression of APC1556. MCF7 and HCT116 cell lines were transfected with pCIN
alone (—) or pCIN expressing the indicated mutant APC. APC proteins were detected by immunoblotting. “wt” indicates the endogenous wild-
type APC. Dots indicate mutant APC proteins. B, Regulation of CRT by APC1556. SW480, DLD-1, and HCT116 cell lines were transfected
with a combination of pRL-TK, pTOPFLASH, and an APC expression vector, as indicated. The unblackened and blackened bars indicate
expression of APC by pCIN and by pCMV-NEO-BAM, respectively. The mean and SD of the result of triplicate experiments are shown. The
activities of the wild-type APC, APC1556, APCdA9, and APCdA,1556 in the regulation of CRT are compared with that of APC1309. (C)
Reduction of b-catenin by APC1556. SW480 cells were transfected with pUHD15-1 and pTBI, expressing indicated APC. Cells were immu-
nostained with a monoclonal antibody against b-catenin. Transfected cells were identified by their expression of green fluorescence protein
(GFP), because pTBI also expressed GFP. Nuclei were revealed by staining with 4,6-diamidino-2-phenylindole (DAPI). Arrowheads indicate
transfected cells.
Other mutations downstream of codon 1500 that oc-
cur less frequently than the 4666insA mutation also may
differentially affect the wild-type APC and APCAS9. The
finding that 4616delAG also occurred on the APCAS9
allele supports this hypothesis. It is also supported by
observations that somatic mutations of APC that are
downstream of codon 1500 are rare in colorectal tu-
mors (Nagase et al. 1992; Powell et al. 1992; Miyaki
et al. 1994). Moreover, patients carrying germline APC
mutations downstream of codon 1500, including those
in a family reported to carry the 4666insA mutation,
usually develop AFAP (Friedl et al. 1996; van der Luijt
et al. 1996; Walon et al. 1997; Soravia et al. 1998).
Future studies of derivatives of human colon cancer cell
lines that can be induced to express different forms of
APC could further clarify the tumor-suppression func-
tion of these APC variants.
These findings provide a model for AFAP in patients
carrying APCAS9. We propose that these patients develop
fewer tumors, and at older ages, than patients with typ-
ical FAP because, although patients with AFAP already
have a germline APC mutation, somatic mutation of
both APC alleles is necessary prior to tumorigenesis.
Nevertheless, patients with AFAP are still predisposed
to colorectal tumorigenesis, becauseAPCAS9 is more eas-
ily inactivated than is wild-type APC, by mutations that
do not significantly affect the tumor-suppressor function
of the wild-type APC (fig. 4). This model for AFAP
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Figure 4 Inactivation of APCAS9, but not wild-type APC, by the 4666insA mutation. “APCF” indicates the full-length APC mRNA. “#”
indicates mutations. “Tumor Suppression” indicates whether each APC allele can function as a tumor suppressor, which is determined by the
combined activities of transcripts of each allele. The mutation 4666insA slightly reduces the activity of proteins encoded by both APCF and
APCdA9 and does not abolish the tumor-suppressor function of APC. APCAS9 does not express full-length APC protein, because its APCF
expresses a severely truncated protein owing to the mutation in the alternatively spliced region of exon 9. However, APCAS9 expresses APCdA9
identical to that expressed by the wild-type APC and has reduced but sufficient tumor-suppressor activity. Further decrease of the reduced
tumor-suppressor activity of APCAS9 by the 4666insA mutation causes APCAS9 to have insufficient tumor-suppressor activity.
caused by APCAS9 also may explain AFAP caused by
APC1–4. Alternative splicing of the first four coding ex-
ons of APC has been demonstrated, and the 4666insA
somatic mutation has been found in the APC1–4 allele
in tumors (Samowitz et al. 1995; Spirio et al. 1998).
However, our model does not readily explain AFAP
caused by APC3H. Although somatic inactivation of
APC3H is probably required for tumor formation,
mutation such as 4666insA is unlikely to inactivate
APC3H. Most reported APC3H alleles have germline mu-
tations downstream of codon 1556. Therefore, a so-
matic 4666insA mutation in these alleles will result in
APC1556, which still has tumor-suppressor activity.
Thus, the data support a model requiring somatic in-
activation of both APC alleles, for tumor formation in
patients with AFAP, although the mechanism for the
increased somatic inactivation of alleles with germline
mutation in different regions of APC may be different.
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Appendix
Summary of APC Alleles, mRNA, and cDNA Described in this Paper
APC1–4 APC alleles that carry germline mutations in the first four coding exons
APCAS9 APC alleles that carry germline mutations in the alternatively spliced region of exon 9
APC3H APC alleles that carry germline mutations in the 3
′ half of the coding region
APCAFAP APC alleles that usually cause AFAP, including APC1–4, APCAS9, and APC3H
APC1556 APC allele or cDNA that carries the 4666insA mutation
APCAS9,1556 APC alleles that carry germline mutations in the alternatively spliced region of exon 9 and the 4666insA mutation
APCdA9 APC mRNA or cDNA that does not have the alternatively spliced region of exon 9
APCdA,1556 APC mRNA or cDNA that does not have the alternatively spliced region of exon 9 and carries the 4666insA mutation
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